• About us
• Contact

Advertisement

Product › Details

H.C. Wainwright BioConnect Conference

	Next higher product group	conference, investment / investor / financing / VC
	Status	2021-01-11 start

Faron Pharmaceuticals Oy. (1/4/21). "Press Release: Faron to Present at H.C. Wainwright BioConnect". Turku.

Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.

An audio webcast of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors


ENDS


For more information please contact:

Stern Investor Relations, Inc.
Julie Seidel, Naina Zaman
Phone: +(1)212 362 1200
Email: faron@sternir.com

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com


About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

Record changed: 2024-05-01

Advertisement

» Show all Events!

H.C. Wainwright BioConnect Conference

Past & forthcoming events

• [1] Baird Global Healthcare Conference    [ ]
• [2] Bank of America Merrill Lynch Global Healthcare Conference (BAML Global Healthcare Conference)    [ ]
• [3] Barclays Gene Editing & Gene Therapy Summit    [ ]
• [4] Barclays Global Healthcare Conference    [ ]
• [5] Berenberg European Conference    [ ]
• [6] BIO Investor Forum    [ ]
• [7] BioCapital Europe conference    [ ]
• [8] Bio€quity Europe (conference)    [ ]
• [9] Bryan, Garnier & Co Annual European Healthcare Conference    [ ]
• [10] Cantor Global Healthcare Conference    [ ]
• [11] Citi Annual BioPharma Conference    [ ]
• [12] Citi European Healthcare Conference    [ ]
• [13] Citi Global Healthcare Conference    [ ]
• [14] Citizens JMP Securities Life Sciences Conference    [ ]
• [15] Consilium Strategic Communications Annual Healthcare Conference    [ ]
• [16] Cowen and Company Annual Health Care Conference    [ ]
• [17] Cowen and Company Annual Therapeutics Conference    [ ]
• [18] Credit Suisse Annual Healthcare Conference    [ ]
• [19] Credit Suisse Global Healthcare Conference London    [ ]
• [20] Credit Suisse Summer Biotech Conference    [ ]
• [21] Deutsche Bank Annual Health Care Conference    [ ]
• [22] DNB Markets Nordic Healthcare Conference    [ ]
• [23] European Large & Midcap Event    [ ]
• [24] Evercore ISI HealthCONx Conference    [ ]
• [25] FT Global Pharma and Biotech Summit    [ ]
• [26] Goldman Sachs Annual Biotech Symposium    [ ]
• [27] Goldman Sachs Annual Global Healthcare Conference    [ ]
• [28] Goldman Sachs European Medtech and Healthcare Services Conference    [ ]
• [29] Goldman Sachs European Small & Mid-Cap Symposium    [ ]
• [30] Goldman Sachs Healthcare CEOs Unscripted Conference    [ ]
• [31] Guggenheim Securities Annual Boston Healthcare Conference    [ ]
• [32] H.C. Wainwright Annual Global Investment Conference    [ ]
• [33] H.C. Wainwright BioConnect Conference    [ 2021-01-11 ]
• [34] H.C. Wainwright Global Life Sciences Conference    [ ]
• [35] J.P. Morgan Annual Healthcare Conference (JPM Healthcare Conference)    [ ]
• [36] J.P. Morgan Annual Napa Conference    [ ]
• [37] J.P. Morgan European Healthcare Conference    [ ]
• [38] J.P. Morgan London Small/Mid Cap Conference (JP Morgan Cazenove Pan-European Small/Mid Cap Conference)    [ ]
• [39] Jefferies Global Healthcare Conference    [ ]
• [40] Jefferies Immuno-Oncology Cell Therapy Summit (Jefferies IO Cell Therapy Summit)    [ ]
• [41] Jefferies London Healthcare Conference    [ ]
• [42] Ladenburg Thalmann Healthcare Conference    [ ]
• [43] Leerink Partners Global Biopharma Conference    [ ]
• [44] LifeSci Advisors Nordic BioTech Summit    [ ]
• [45] Morgan Stanley Annual Global Healthcare Conference    [ ]
• [46] Morgan Stanley Annual Laguna Conference    [ ]
• [47] Needham & Co. Annual Healthcare Conference    [ ]
• [48] Oppenheimer & Co. Annual Healthcare Conference    [ ]
• [49] Pareto Securities Annual Healthcare Conference    [ 2000-01-01 ]
• [50] Piper Sandler Annual Healthcare Conference (formerly Piper Jaffray)    [ ]
• [51] RBC Capital Markets Global Healthcare Conference    [ ]
• [52] Rodman & Renshaw Annual Global Investment Conference    [ ]
• [53] Roth Capital Partners Annual Conference    [ ]
• [54] Sachs Annual European Life Sciences CEO Forum (ELSF)    [ ]
• [55] Sachs Annual European MT&DH Forum    [ ]
• [56] Stifel Nicolaus Weisel Healthcare Conference    [ ]
• [57] SVB Leerink CybeRx Series    [ ]
• [58] UBS Global Healthcare Conference    [ ]
• [59] Wedbush PacGrow Healthcare Conference    [ ]

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.